Fujisawa's Antifungal Mycamine Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The product will be rolled out by the summer, with detailing by Fujisawa's existing immunology and hospital sales forces. Micafungin is approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment of esophageal candidiasis.
You may also be interested in...
Astellas Wins Additional Indications For Antifungal Mycamine
Injectable for Candida infections gets FDA okay for candidemia, acute disseminated candidiasis, candida peritonitis and abscesses.
Astellas Wins Additional Indications For Antifungal Mycamine
Injectable for Candida infections gets FDA okay for candidemia, acute disseminated candidiasis, candida peritonitis and abscesses.
Roche Will Co-Promote Fujisawa's Mycamine With Rociphen Sales Force
Roche's hospital sales force will "augment" Fujisawa's promotion of the antifungal. Roche will be compensated based on product sales. Mycamine will be available within the next month, Fujisawa says.